Pelvic lymphadenectomy does not improve survival in early stage endometrial cancer
Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study. Statistical significance was evidenced at all doses tested (25, 100, and 150 mg equivalent [eq.a]), when given every 4 weeks with a 150 mg eq. initiation dose. A separate 53-week non-inferiority trial(b)
Full Post: Paliperidone palmitate shows positive results for treatment of schizophrenia
Systematic use of pelvic lymphadenectomy (removal of the lymph nodes) does not improve disease-free or overall survival in women with early-stage endometrial cancer, according to a randomized trial published online November 25 in the Journal of the National Cancer Institute.
The first site of metastasis for endometrial cancer is often the pelvic lymph nodes. However, few prospective studies have examined whether systematic removal of the pelvic lymph nodes improves patient outcomes.
To find out, Pierluigi Benedetti Panici, M.D., of the La Sapienza University in Rome and colleagues conducted a randomized controlled trial in which women with stage I endometrial cancer were assigned to have a standard hysterectomy and ovary removal with or without lymphadenectomy.
With a median follow-up of four years, there was no difference in patient outcomes between the two arms. Thirty-four (12.9 percent) of the 264 patients in the lymphadenectomy group and 33 (13.2 percent) of the 250 patients in the control group had disease recurrence. The median time to disease recurrence was 14 months in the lymphadenectomy arm and 13 months in the control arm. Overall five-year survival estimates were 86 percent for the lymphadenectomy arm and 90 percent for the non-lymphadenectomy.
Surgical staging of the disease was improved with the systematic use of lymphadenectomy. A total of 13.3 percent of the women in the lymphadenectomy arm were found to have disease spread to pelvic lymph nodes, compared with 3.2 percent of the women in the control arm. The investigators found that although lymphadenectomy was not statistically significantly associated with improved survival, disease spread to the nodes was associated with poorer survival.
“Therefore, lymph?adenectomy maintained its importance in determining a patient’s prognosis and in tailoring adjuvant therapies,” the authors conclude.
In an accompanying editorial, Christine Walsh, M.D., and Beth Karlan, M.D., of the Cedars-Sinai Medical Center in Los Angeles note that these new data are consistent with the one other randomized trial that examined the impact of lymphadenectomy on survival.
“These results bust the myth that is based on previous retrospective studies that lymphadenectomy, in and of itself, provides therapeutic ben?efit and survival advantage in endometrial cancer,” the editorialists write. “Yet, this trial continues to support the notion that lymphadenectomy can pro?vide important prognostic information and can help guide adju?vant treatment recommendations.”
Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Patients using aromatase inhibitors had more than a 3 percent lower cancer recurrence
Full Post: Aromatase inhibitors most effective in preventing breast cancer from coming back
The American Society for Gastrointestinal Endoscopy (ASGE) heralds the recent news of a decline in U.S. cancer deaths and incidence rates, with colorectal cancer among the top three cancers with significant declines. ASGE, representing the specialists in colorectal cancer screening, is excited by the report showing that colorectal cancer deaths among men and women dropped
Full Post: ASGE encouraged by drop in colorectal cancer deaths
The German Cancer Society has worked out new guidelines for the diagnosis and treatment of malignant melanoma - a disease with unfavorable prognosis. Malignant melanoma is responsible for 90% of deaths from skin cancer. The incidence has increased 5-fold within the last 30 years and UV radiation is thought to be an important cause. Caucasian
Full Post: New guidelines for malignant melanoma
Diabetes appears to be linked with an increased risk of pelvic girdle syndrome. This is shown in a new study from the Norwegian Institute of Public Health and Akershus University Hospital. The study showed that five percent of women had had serious pelvic girdle syndrome (pain in both iliosacral ligaments and symphysis pubis) during their
Full Post: Pelvic girdle syndrome linked to diabetes
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center. The findings, presented today
Full Post: Early-stage breast cancer patients with HER2 positive tumors at increased risk of recurrence